Table 1.
Characteristics of the included randomized controlled trials.
| Author | Year | Country | Type of intervention | Outcome | Intervention (events/total) | Control (events/total) | Follow-up |
|---|---|---|---|---|---|---|---|
| Komulainen et al. (49) | 2023 | Finland | Fish oil capsule | Any IgE-associated disease | 11/65 | 19/64 | 24 months |
| Hansen et al. (50) | 2017 | Denmark | Fish oil capsule | IgE-associated asthma (EPA-rich) | 31/262 | 28/134 | 24 months |
| IgE-mediated rhinoconjunctivitis | 57/262 | 40/134 | |||||
| Bisgaard et al. (17) | 2016 | Denmark | Fish oil capsule | IgE-associated asthma | 58/346 | 78/349 | 3–5 years |
| IgE-associated eczema | 114/346 | 99/349 | |||||
| IgE-mediated rhinoconjunctivitis | 33/324 | 45/321 | |||||
| Berman et al. (5) | 2016 | USA | Fish oil capsule | IgE-associated asthma (EPA-rich) | 13/31 | 3/27 | 36 months |
| IgE-mediated food reaction (EPA-rich) | 4/30 | 3/27 | |||||
| IgE-associated eczema (EPA-rich) | 9/31 | 7/27 | |||||
| IgE-associated asthma (EPA-rich) | 10/26 | 3/27 | |||||
| IgE-mediated food reaction (DHA-rich) | 5/26 | 3/27 | |||||
| IgE-associated eczema (DHA-rich) | 4/26 | 7/27 | |||||
| Best et al. (16) | 2016 | Australia | Fish oil capsule | Any IgE-associated disease | 116/367 | 106/336 | 6 years |
| Noakes et al. (19) | 2012 | UK | Salmon | Any positive SPT | 6/48 | 5/38 | 6 months |
| Furuhjelm et al. (14) | 2011 | Sweden | Fish oil capsule | Any IgE-associated disease | 6/54 | 19/62 | 24 months |
| Dunstan et al. (51) | 2003 | Australia | Fish oil capsule | Any positive SPT | 9/35 | 14/37 | 12 months |
EPA, Eicosapentaenoic Acid; DHA, Docosahexaenoic Acid; SPT, Skin Prick Test; IgE, Immunoglobulin E.